This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Abiomed Dirección

Dirección controles de criterios 3/4

Información clave

Mike Minogue

Chief Executive Officer (CEO)

US$12.7m

Compensación total

Porcentaje del salario del CEO	6.2%
Permanencia del CEO	18.7yrs
Participación del CEO	0.8%
Permanencia media de la dirección	4.5yrs
Promedio de permanencia en la Junta Directiva	8.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mike Minogue en comparación con los beneficios de Abiomed?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2022	n/a	n/a	US$267m
Jun 30 2022	n/a	n/a	US$218m
Mar 31 2022	US$13m	US$789k	US$137m
Dec 31 2021	n/a	n/a	US$133m
Sep 30 2021	n/a	n/a	US$149m
Jun 30 2021	n/a	n/a	US$154m
Mar 31 2021	US$15m	US$608k	US$226m
Dec 31 2020	n/a	n/a	US$200m
Sep 30 2020	n/a	n/a	US$208m
Jun 30 2020	n/a	n/a	US$159m
Mar 31 2020	US$17m	US$768k	US$203m
Dec 31 2019	n/a	n/a	US$245m
Sep 30 2019	n/a	n/a	US$221m
Jun 30 2019	n/a	n/a	US$258m
Mar 31 2019	US$19m	US$753k	US$259m
Dec 31 2018	n/a	n/a	US$222m
Sep 30 2018	n/a	n/a	US$190m
Jun 30 2018	n/a	n/a	US$165m
Mar 31 2018	US$10m	US$718k	US$112m
Dec 31 2017	n/a	n/a	US$90m
Sep 30 2017	n/a	n/a	US$92m
Jun 30 2017	n/a	n/a	US$77m
Mar 31 2017	US$12m	US$649k	US$52m
Dec 31 2016	n/a	n/a	US$48m
Sep 30 2016	n/a	n/a	US$43m
Jun 30 2016	n/a	n/a	US$42m
Mar 31 2016	US$19m	US$630k	US$38m

Compensación vs. Mercado: Mike's total compensation ($USD12.67M) is above average for companies of similar size in the German market ($USD4.81M).

Compensación vs. Ingresos: Mike's compensation has been consistent with company performance over the past year.

CEO

Mike Minogue (55 yo)

18.7yrs

Permanencia

US$12,665,992

Compensación

Mr. Michael R. Minogue, also known as Mike, served as Director at Medical Device Innovation Consortium, previously served as its chairman until June 2019. He has been Chief Executive Officer and President...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Minogue	Chairman	18.7yrs	US$12.67m	0.77% $ 125.4m
Todd Trapp	Executive VP & CFO	4.7yrs	US$3.04m	0.017% $ 2.7m
Marc Began	Executive VP	4.5yrs	US$2.57m	0.027% $ 4.4m
Andrew Greenfield	Executive VP & Chief Commercial Officer	2.7yrs	US$2.84m	0.045% $ 7.4m
David Weber	Scientific & Technology Advisor	less than a year	US$2.29m	0.30% $ 49.1m
Matthew Plano	Executive Vice President of Global Operations & Integration	no data	sin datos	0.017% $ 2.8m
Thorsten Siess	Executive VP & Chief Technology Officer	no data	sin datos	sin datos
Ingrid Ward	Director of Investor Relations	8.3yrs	sin datos	sin datos
Sarah Karr	Communications Manager	no data	sin datos	sin datos
Michael Howley	VP & GM of Global Sales	13.8yrs	US$1.71m	sin datos
Karen Mahoney	VP & Chief Human Resources Officer	3.3yrs	sin datos	sin datos
Charles Simonton	Executive VP & Chief Medical Officer	2.5yrs	sin datos	sin datos

4.5yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: AIO's management team is considered experienced (4.5 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Minogue	Chairman	18.7yrs	US$12.67m	0.77% $ 125.4m
Martin Sutter	Independent Director	14.6yrs	US$266.80k	0.26% $ 42.6m
Jeannine Rivet	Independent Director	6.8yrs	US$266.80k	0.021% $ 3.3m
Paul Thomas	Independent Director	11.6yrs	US$269.30k	0.013% $ 2.0m
Eric Rose	Independent Director	8.3yrs	US$259.30k	0.032% $ 5.2m
Dorothy Puhy	Independent Lead Director	19.3yrs	US$299.30k	0.032% $ 5.1m
Paula Johnson	Independent Director	1.7yrs	US$499.89k	0.0011% $ 179.7k
Christopher Van Gorder	Independent Director	6.8yrs	US$264.30k	0.015% $ 2.4m
Myron Rolle	Independent Director	1.8yrs	US$259.30k	0.0011% $ 184.6k

8.3yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: AIO's board of directors are considered experienced (8.3 years average tenure).

This company listing is no longer active

Abiomed Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold €1.0m worth of stock

Independent Director recently sold €4.5m worth of stock

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Second quarter 2023 earnings released: EPS: US$2.34 (vs US$1.25 in 2Q 2022)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold €1.0m worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

Abiomed, Inc. (NasdaqGS:ABMD) acquired all the assets and business from Sensera, Inc. for $7.5 million on January 4, 2022.

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold €4.5m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Revenue beats expectations

New 90-day high: €310

Abiomed, Inc. to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: €267

New 90-day low: €216

Second quarter 2021 earnings released: EPS US$1.38

Revenue beats expectations

Abiomed Announces FDA Grants 510(k) Clearance for the Company's Innovative Cardiopulmonary Support Technology

Abiomed, Inc. Announces New Protect Iii Study Data That Demonstrates Reduced Rates of MACCE

Abiomed, Inc. to Report Q2, 2021 Results on Oct 29, 2020

Abiomed, Inc. Not to Provide Earnings Guidance for the Fiscal Year 2021

New 90-day high - €263

Abiomed, Inc. (NasdaqGS:ABMD) acquired the remaining stake in Breethe, Inc.

Abiomed, Inc. to Report Q1, 2021 Results on Aug 06, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad